Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole-carboxamide in human plasma

被引:35
作者
Liu, Yanhong [3 ]
Zhang, Weihua [2 ]
Yang, Yuhui [1 ]
机构
[1] Chrom Matrix Inc, Richland, WA 99354 USA
[2] Gansu Prov Canc Hosp, Lanzhou 730001, Peoples R China
[3] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Minist Agr, Key Lab Anim Virol,State Key Lab Vet Etiol Biol, Lanzhou 730046, Peoples R China
关键词
Dacarbazine; 5-Amino-4-imidazole-carboxamide; Matrix effect; Carryover; Hydrophilic interaction chromatography; LC-MS/MS; Primary and secondary amine; Pharmacokinetics;
D O I
10.1016/j.talanta.2008.07.004
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A hydrophilic interaction high performance liquid chromatography-tandem mass spectrometric method has been developed and validated for simultaneous quantification of dacarbazine (DTIC) and its terminal metabolite, 5-amino-4-imidazole-carboxamide (AIC) in human plasma. The plasma samples are first extracted by a C8 + SCX mixed-mode 96-well plate to extend the extraction stability of DTIC and AIC. The extracted residues are further cleaned by a primary and secondary amine (PSA) adsorbent for minimization of matrix effect. Analyses are done on an Amide-80 HPLC column coupled to a tandem mass spectrometer fitted with an atmospheric pressure turbo ion spray ionization interface in the positive-ion mode. Both DTIC and AIC have reproducible retention times on the Amide-80 HPLC column. This type of column not only has an excellent column life (over 4000 injections), but also has zero carryover effect. The injection volume should be limited at 10 mu L or less to avoid the peak splitting. The validated concentration ranges are from 0.5 to 500 ng/mL for DTIC and from 2.0 to 500 ng/mL for AIC. The validated method has been successfully applied to determine the pharmacokinetic profiles for human patients receiving DTIC infusions. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:412 / 421
页数:10
相关论文
共 26 条
[1]  
[Anonymous], 2001, FED REGISTER, V66, P28526
[2]  
Bennett PK, 2003, 2003 AAPS ANN M EXP
[3]  
*BENV LAB, 2006, DTIC DOM PROD MAN
[4]   PHARMACOKINETICS OF DACARBAZINE (DTIC) AND ITS METABOLITE 5-AMINOIMIDAZOLE-4-CARBOXAMIDE (AIC) FOLLOWING DIFFERENT DOSE SCHEDULES [J].
BREITHAUPT, H ;
DAMMANN, A ;
AIGNER, K .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (02) :103-109
[5]   CLINICAL PHARMACOKINETICS OF HIGH-DOSE DTIC [J].
BUESA, JM ;
URRECHAGA, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (06) :475-479
[6]   Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma [J].
Chapman, PB ;
Einhorn, LH ;
Meyers, ML ;
Saxman, S ;
Destro, AN ;
Panageas, KS ;
Begg, CB ;
Agarwala, SS ;
Schuchter, LM ;
Ernstoff, MS ;
Houghton, AN ;
Kirkwood, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2745-2751
[7]   An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma [J].
Chowdhury, SK ;
Laudicina, D ;
Blumenkrantz, N ;
Wirth, M ;
Alton, KB .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 19 (05) :659-668
[8]  
DEVITA VTJ, 2005, CANC PRINCIPLES PRAC
[9]   Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? [J].
Eggermont, AMM ;
Kirkwood, JM .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (12) :1825-1836
[10]  
Fazeny-Dörner B, 2004, ANTI-CANCER DRUG, V15, P495, DOI 10.1097/01.cad.0000127145.50172.51